Published in Medical Letter on the CDC and FDA, November 7th, 2004
Andre Aube, Magistral's president and CEO said, "we would not risk pairing our product with a drug of the caliber of Lipitor unless we were highly confident that we would obtain a superior efficacy rate than with the drug alone, while at the same time preventing side effects." This clinical study will compare the effects of the two products in combination therapy with results obtained by patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA